Armed with new pivotal trial results, Eli Lilly plans to file for approval of its keenly anticipated new weight-loss therapy, ...

After a delay of several years, people living with multiple sclerosis in England will finally be able to get NHS access to ...

GSK has won FDA approval for Jideytro, a drug at the heart of its $10.6 billion acquisition of Nuvalent earlier this year – ...

China has become the first country to approve Takeda's first-in-class orexin agonist, oveporexton, for the sleep disorder ...

Donald Trump has said he intends to impose tariffs of 100% on generic drugs imported into the US from 2028, as part of a ...

Life sciences equipment and consumable manufacturer Repligen has reached a deal to buy cell therapy specialist BioLife ...

Precision Neuro published a video yesterday showcasing clinical research carried out using its investigational BCI system, ...

Gilead Sciences and MSD's once-weekly oral medicine for HIV has been shown to achieve high rates of viral load suppression in ...

The intense rivalry between Novo Nordisk and Eli Lilly in the market for GLP-1 agonist-based therapies for obesity and type 2 ...

Jonathan Reynolds will lead the new combined Department for Business, Innovation, Science and Trade (DBIST). In the midst of ...

However, while access to this information has never been easier, trust in these resources grows increasingly fragile. Faced ...

Agios Pharma has said it will halt clinical development of tebapivat, a PK activator that had reached phase 2 testing in ...